These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 29122656)

  • 1. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
    Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
    Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
    Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
    Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
    Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
    Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
    Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Genetic Alterations Involving PD-L1/PD-L2 in Human Malignancies].
    Kataoka K
    Gan To Kagaku Ryoho; 2019 May; 46(5):841-844. PubMed ID: 31189800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.
    Zanelli M; Fragliasso V; Parente P; Bisagni A; Sanguedolce F; Zizzo M; Broggi G; Ricci S; Palicelli A; Foroni M; Gozzi F; Gentile P; Morini A; Koufopoulos N; Caltabiano R; Cimino L; Fabozzi M; Cavazza A; Neri A; Ascani S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
    Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
    J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
    Xerri L; Chetaille B; Serriari N; Attias C; Guillaume Y; Arnoulet C; Olive D
    Hum Pathol; 2008 Jul; 39(7):1050-8. PubMed ID: 18479731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
    Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
    Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
    Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
    Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
    Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
    Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
    Wolkow N; Jakobiec FA; Afrogheh AH; Pai SI; Faquin WC
    Am J Ophthalmol; 2020 Dec; 220():128-139. PubMed ID: 32730911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
    Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
    BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
    Xu J; Sun HH; Fletcher CD; Hornick JL; Morgan EA; Freeman GJ; Hodi FS; Pinkus GS; Rodig SJ
    Am J Surg Pathol; 2016 Apr; 40(4):443-53. PubMed ID: 26752545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Status in Refractory Lymphomas.
    Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
    PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
    Xu-Monette ZY; Zhou J; Young KH
    Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.